Trump Slaps Massive New Tariffs on Metals and Drugs, Threatening Price Spikes and Supply Chain Chaos

Another Trump Tariff Bomb Drops on American Consumers

On April 2, 2026, Donald Trump signed two proclamations that will jack up prices on everything from construction materials to prescription drugs, all under the guise of "national security." Using Section 232 of the Trade Expansion Act—a Cold War-era law meant for actual security threats—Trump imposed punishing tariffs on metals and pharmaceuticals that will take effect within months.

The administration is calling it trade policy. What it actually is: a massive tax increase on American businesses and consumers, with convenient carve-outs for companies willing to play ball with Trump's Commerce Department.

Metals Tariffs: Pay Up or Move Your Factory

Starting April 6, 2026, importers of steel, aluminum, and copper products face tariffs of up to 50 percent on the full value of their goods—not just the metal content, as previous rules allowed. That means a steel-containing machine part that used to face tariffs on 30 percent of its value now gets hit on 100 percent.

The proclamation divides covered products into two categories. Standard metal articles in tariff chapters 72, 73, 74, and 76 face 50 percent duties. Derivative products—the more than 400 items Trump's Commerce Department added to the tariff list in August 2025—face 25 percent duties. Both rates represent significant increases that will ripple through construction, manufacturing, and infrastructure projects.

There are exceptions, of course. Products from the United Kingdom get reduced rates of 25 percent or 15 percent depending on the category. Goods made entirely with U.S.-origin metal qualify for just 10 percent duties. The message is clear: move your supply chain to America or countries Trump favors, or pay through the nose.

The proclamation carves out some metal-intensive industrial equipment and electrical grid components for a temporary 15 percent rate through 2027. Products containing 15 percent or less metal by weight escape the tariffs entirely. But for most importers, the new rules mean significantly higher costs that will inevitably get passed to consumers.

Pharmaceutical Tariffs: 100 Percent Duties Unless You Cut a Deal

The second proclamation takes aim at patented pharmaceuticals and their ingredients, imposing tariffs that make the metals duties look modest by comparison. Starting July 31, 2026 for large companies and September 29, 2026 for everyone else, imports of patented drugs and their ingredients will face 100 percent tariffs—effectively doubling their cost.

Unless, that is, companies agree to Trump's terms.

Companies that sign "Commerce-recognized onshoring commitments"—promising to move manufacturing to the U.S.—get their rate cut to 20 percent. That sweetheart deal expires in 2030, when rates jump back to 100 percent. Companies that also agree to "Most-Favored-Nation" pricing deals with the Department of Health and Human Services can get their tariffs reduced to zero until January 2029.

This is not trade policy. This is extortion dressed up in proclamation language.

Imports from Japan, the European Union, South Korea, Switzerland, and Liechtenstein face 15 percent duties. The UK gets 10 percent, potentially dropping to zero if the British government complies with a separate pharmaceutical agreement. These carve-outs reward allies willing to negotiate on Trump's terms while punishing everyone else.

The proclamation excludes generic drugs—for now. It also exempts specialty pharmaceuticals including orphan drugs, nuclear medicines, plasma therapies, fertility treatments, and other categories. But the Commerce Secretary retains authority to expand the tariff regime at any time.

Who Really Pays for Trump's Tariffs

Trump has repeatedly claimed that foreign countries pay tariffs. That is false. American importers pay tariffs to U.S. Customs and Border Protection, then pass those costs to businesses and consumers through higher prices.

These new tariffs will hit American manufacturers who rely on imported metals and components. They will hit construction companies building infrastructure. They will hit pharmaceutical companies and, ultimately, patients who need medications. The Congressional Budget Office and independent economists have consistently found that tariffs function as regressive taxes that hit lower-income Americans hardest.

The proclamations include some technical relief mechanisms. Companies can use "privileged foreign status" for goods in foreign trade zones. Drawback—refunds of duties on re-exported goods—remains available for pharmaceuticals but stays limited for metals. These provisions help some large importers but do nothing for smaller businesses or end consumers.

Cronyism Baked Into the Fine Print

The pharmaceutical tariff structure reveals the real game. Companies that negotiate onshoring commitments with the Commerce Department get massive rate reductions. Companies that refuse face 100 percent duties that could make their products uncompetitive.

This creates enormous leverage for Trump administration officials to extract concessions from pharmaceutical companies. Want to avoid tariffs that would destroy your business? Better start building factories in red states and agreeing to drug pricing schemes that benefit Trump politically.

The metals tariffs follow a similar pattern. U.S.-origin content gets preferential treatment. UK products get better rates than other allies. The administration retains authority to revise the framework for countries that "enter into onshoring or MFN agreements or fail to fulfill such agreements"—translation: we can change the rules whenever we want to reward friends and punish enemies.

What Happens Next

These proclamations take effect within weeks. Companies throughout affected industries are scrambling to assess their exposure and figure out whether they can absorb the costs, pass them to customers, or restructure their supply chains entirely.

The administration claims this is about national security. But Section 232 was designed for genuine security threats like wartime shortages, not peacetime protectionism. Trump is abusing emergency powers to impose tariffs that Congress would never approve through normal legislative process.

American consumers will pay the price—literally—through higher costs for construction, manufacturing, and prescription drugs. Meanwhile, companies that play ball with Trump's Commerce Department will get sweetheart deals that their competitors cannot access.

That is not national security policy. That is corruption with a tariff schedule attached.